阿普米司特在斑块状银屑病治疗中的研究进展

doi:10.35541/cjd.20230448

Abstract

Abstract: 【Abstract】 Psoriasis is a chronic inflammatory systemic disease induced by multiple immune cells. Apremilast, an orally administered small-molecule phosphodiesterase 4 inhibitor, is effective in the treatment of psoriasis by inhibiting the activity of intracellular phosphodiesterase 4, indirectly elevating intracellular cyclic adenosine monophosphate levels, achieving a balance between the expression of pro-inflammatory and anti-inflammatory factors, and thus restoring immune homeostasis. This review summarizes the efficacy and safety of apremilast in the treatment of plaque psoriasis and its application in special populations.

Key words: Psoriasis, Phosphodiesterase 4 inhibitors, Cyclic nucleotide phosphodiesterases, Apremilast, Efficacy

Zhu Tingting, Zhang Xuejun. Apremilast in the treatment of plaque psoriasis[J]. Chinese Journal of Dermatology,2024,e20230448. doi:10.35541/cjd.20230448

References ［70］

［1］	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2023版）［J］. 中华皮肤科杂志, 2023,56（7）:573⁃625. doi: 10.35541/cjd.20220839.
［2］	GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019［J］. Lancet, 2020,396（10258）:1204⁃1222. doi: 10. 1016/S0140⁃6736（20）30925⁃9.
［3］	Strychalski ML, Brown HS, Bishop SC. Cytokine modulators in plaque psoriasis ⁃ a review of current and prospective biologic therapeutic approaches［J］. JAAD Int, 2022,27（9）:82⁃91. doi: 10.1016/j.jdin.2022.08.008.
［4］	Parab S, Doshi G. An update on emerging immunological targets and their inhibitors in the treatment of psoriasis［J］. Int Immunopharmacol, 2022,113（Pt A）:109341. doi: 10.1016/j.intimp. 2022.109341.
［5］	Lin CP, Merola JF, Wallace EB. Current and emerging biologic and small molecule systemic treatment options for psoriasis and psoriatic arthritis［J］. Curr Opin Pharmacol, 2022,67:102292. doi: 10.1016/j.coph.2022.102292.
［6］	Hari G, Kishore A, Karkala S. Treatments for psoriasis: a journey from classical to advanced therapies. How far have we reached?［J］. Eur J Pharmacol, 2022,929:175147. doi: 10.1016/j.ejphar. 2022.175147.
［7］	Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population⁃based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey［J］. J Am Acad Dermatol, 2014,70（5）:871⁃881. doi: 10.1016/j.jaad.2013.12.018.
［8］	Thakur V, Mahajan R. Novel therapeutic target（s） for psoriatic disease［J］. Front Med （Lausanne）, 2022,9:712313. doi: 10. 3389/fmed.2022.712313.
［9］	Gao JC, Wu AG, Contento MN, et al. Apremilast in the treatment of plaque psoriasis: differential use in psoriasis［J］. Clin Cosmet Investig Dermatol, 2022,15:395⁃402. doi: 10.2147/CCID.S266036.
［10］	Abushal AS, Aleanizy FS, Alqahtani FY, et al. Self⁃nanoemulsifying drug delivery system （SNEDDS） of apremilast: in vitro evaluation and pharmacokinetics studies［J］. Molecules, 2022,27（10）:3085. doi: 10.3390/molecules27 103085.
［11］	Schmidt M, Dekker FJ, Maarsingh H. Exchange protein directly activated by cAMP （epac）: a multidomain cAMP mediator in the regulation of diverse biological functions［J］. Pharmacol Rev, 2013,65（2）:670⁃709. doi: 10.1124/pr.110.003707.
［12］	Li H, Zuo J, Tang W. Phosphodiesterase⁃4 inhibitors for the treatment of inflammatory diseases［J］. Front Pharmacol, 2018,9:1048. doi: 10.3389/fphar.2018.01048.
［13］	Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris ⁃ part 1: treatment and monitoring recommendations［J］. J Eur Acad Dermatol Venereol, 2020,34（11）:2461⁃2498. doi: 10.1111/jdv.16915.
［14］	Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris ⁃ part 2: specific clinical and comorbid situations［J］. J Eur Acad Dermatol Venereol, 2021,35（2）:281⁃317. doi: 10.1111/jdv.16926.
［15］	Menter A, Strober BE, Kaplan DH, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with biologics［J］. J Am Acad Dermatol, 2019,80（4）:1029⁃1072. doi: 10.1016/j.jaad.2018.11.057.
［16］	Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology⁃National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies［J］. J Am Acad Dermatol, 2020,82（6）:1445⁃1486. doi: 10.1016/j.jaad.2020.02.044.
［17］	Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 （PDE4） inhibitor, in patients with moderate to severe plaque psoriasis: results of a phaseⅢ, randomized, controlled trial （efficacy and safety trial evaluating the effects of apremilast in psoriasis ［ESTEEM］ 1）［J］. J Am Acad Dermatol, 2015,73（1）:37⁃49. doi: 10.1016/j.jaad.2015.03. 049.
［18］	Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate⁃to⁃severe plaque psoriasis over 52 weeks: a phaseⅢ, randomized controlled trial （ESTEEM 2）［J］. Br J Dermatol, 2015,173（6）:1387⁃1399. doi: 10.1111/bjd.14164.
［19］	Ioannides D, Antonakopoulos N, Georgiou S, et al. Effectiveness and safety of apremilast in biologic⁃naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study［J］. J Eur Acad Dermatol Venereol, 2021,35（9）:1838⁃1848. doi: 10.1111/jdv.17392.
［20］	Reich K, Gooderham M, Bewley A, et al. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study［J］. J Eur Acad Dermatol Venereol, 2018,32（3）:397⁃402. doi: 10. 1111/jdv.14738.
［21］	Stein Gold L, Bagel J, Lebwohl M, et al. Efficacy and safety of apremilast in systemic⁃ and biologic⁃naive patients with moderate plaque psoriasis: 52⁃week results of UNVEIL［J］. J Drugs Dermatol, 2018,17（2）:221⁃228.
［22］	Van Voorhees AS, Stein Gold L, Lebwohl M, et al. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: results of a phase 3b, multicenter, randomized, placebo⁃controlled, double⁃blind study［J］. J Am Acad Dermatol, 2020,83（1）:96⁃103. doi: 10.1016/j.jaad.2020. 01.072.
［23］	Van Voorhees AS, Stein Gold L, Lebwohl M, et al. Efficacy and safety of apremilast in patients with moderate⁃to⁃severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phaseⅢ study［J］. Br J Dermatol, 2021,185（4）:840⁃842. doi: 10.1111/bjd.20083.
［24］	Stein Gold L, Papp K, Pariser D, et al. Efficacy and safety of apremilast in patients with mild⁃to⁃moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double⁃blind, placebo⁃controlled trial［J］. J Am Acad Dermatol, 2022,86（1）:77⁃85. doi: 10.1016/j.jaad.2021.07.040.
［25］	Strober B, Bagel J, Lebwohl M, et al. Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower BSA: week 16 results from the UNVEIL study［J］. J Drugs Dermatol, 2017,16（8）:801⁃808.
［26］	Strober B, Alikhan A, Lockshin B, et al. Apremilast mechanism of efficacy in systemic⁃naive patients with moderate plaque psoriasis: pharmacodynamic results from the UNVEIL study［J］. J Dermatol Sci, 2019,96（3）:126⁃133. doi: 10.1016/j.jdermsci. 2019.09.003.
［27］	Muñoz⁃Santos C, Sola⁃Ortigosa J, Vidal D, et al. Apremilast improves quality of life and ultrasonography parameters in patients with nail psoriasis: a prospective cohort study［J］. J Dermatol, 2021,48（10）:1593⁃1596. doi: 10.1111/1346⁃8138. 16074.
［28］	Lanna C, Cesaroni GM, Mazzilli S, et al. Apremilast as a target therapy for nail psoriasis: a real⁃life observational study proving its efficacy in restoring the nail unit［J］. J Dermatolog Treat, 2022,33（2）:1097⁃1101. doi: 10.1080/09546634.2020.1801976.
［29］	Merola JF, Parish LC, Guenther L, et al. Efficacy and safety of apremilast in patients with moderate⁃to⁃severe genital psoriasis: results from discreet, a phase 3 randomized, double⁃blind, placebo⁃controlled trial［J］. J Am Acad Dermatol, 2023. doi: 10.1016/j.jaad.2023.10.020.
［30］	Mrowietz U, Barker J, Conrad C, et al. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: results from the EMBRACE randomized trial［J］. J Eur Acad Dermatol Venereol, 2023,37（2）:348⁃355. doi: 10.1111/jdv.18689.
［31］	Bissonnette R, Pariser DM, Wasel NR, et al. Apremilast, an oral phosphodiesterase⁃4 inhibitor, in the treatment of palmoplantar psoriasis: results of a pooled analysis from phase II PSOR⁃005 and phaseⅢ efficacy and safety trial evaluating the effects of apremilast in psoriasis （ESTEEM） clinical trials in patients with moderate to severe psoriasis［J］. J Am Acad Dermatol, 2016,75（1）:99⁃105. doi: 10.1016/j.jaad.2016.02.1164.
［32］	Wilsmann⁃Theis D, Kromer C, Gerdes S, et al. A multicentre open⁃label study of apremilast in palmoplantar pustulosis （APLANTUS）［J］. J Eur Acad Dermatol Venereol, 2021,35（10）:2045⁃2050. doi: 10.1111/jdv.17441.
［33］	Reich K, Korge B, Magnolo N, et al. Quality⁃of⁃life outcomes, effectiveness and tolerability of apremilast in patients with plaque psoriasis and routine german dermatology care: results from LAPIS⁃PSO［J］. Dermatol Ther （Heidelb）, 2022,12（1）:203⁃221. doi: 10.1007/s13555⁃021⁃00658⁃x.
［34］	Kavanaugh A, Mease PJ, Gomez⁃Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo⁃controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor［J］. Ann Rheum Dis, 2014,73（6）:1020⁃1026. doi: 10.1136/annrheumdis⁃ 2013⁃205056.
［35］	Cutolo M, Myerson GE, Fleischmann RM, et al. A PhaseⅢ, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial［J］. J Rheumatol, 2016,43（9）:1724⁃1734. doi: 10.3899/jrheum.151376.
［36］	Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phaseⅢ, randomised, controlled trial （PALACE 3）［J］. Ann Rheum Dis, 2016,75（6）:1065⁃1073. doi: 10.1136/annrheumdis⁃2015⁃207963.
［37］	Wells AF, Edwards CJ, Kivitz AJ, et al. Apremilast monotherapy in DMARD⁃naive psoriatic arthritis patients: results of the randomized, placebo⁃controlled PALACE 4 trial［J］. Rheumatology （Oxford）, 2018,57（7）:1253⁃1263. doi: 10.1093/rheumatology/key032.
［38］	Nash P, Ohson K, Walsh J, et al. Early and sustained efficacy with apremilast monotherapy in biological⁃naive patients with psoriatic arthritis: a phaseⅢB, randomised controlled trial （ACTIVE）［J］. Ann Rheum Dis, 2018,77（5）:690⁃698. doi: 10. 1136/annrheumdis⁃2017⁃211568.
［39］	Malara G, Politi C, Trifirò C, et al. Effectiveness of apremilast in real life in patients with psoriasis: a longitudinal study［J］. Acta Derm Venereol, 2021,101（9）:adv00545. doi: 10.2340/00015555⁃3846.
［40］	Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult⁃to⁃treat nail and scalp psoriasis: results of 2 phaseⅢ randomized, controlled trials （ESTEEM 1 and ESTEEM 2）［J］. J Am Acad Dermatol, 2016,74（1）:134⁃142. doi: 10.1016/j.jaad.2015.09.001.
［41］	Ferguson LD, Cathcart S, Rimmer D, et al. Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease⁃results of the immune metabolic associations in psoriatic arthritis study［J］. Rheumatology （Oxford）, 2022,61（3）:1026⁃1034. doi: 10.1093/rheumatology/keab474.
［42］	Ikumi K, Torii K, Sagawa Y, et al. Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients［J］. J Dermatol, 2022,49（4）:e125⁃e126. doi: 10.1111/1346⁃8138.16286.
［43］	Pina Vegas L, Le Corvoisier P, Penso L, et al. Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study［J］. Rheumatology （Oxford）, 2022,61（4）:1589⁃1599. doi: 10.1093/rheumatology/keab522.
［44］	Ikonomidis I, Pavlidis G, Kadoglou N, et al. Apremilast improves endothelial glycocalyx integrity, vascular and left ventricular myocardial function in psoriasis［J］. Pharmaceuticals （Basel）, 2022,15（2）:172. doi: 10.3390/ph15020172.
［45］	Takamura S, Sugai S, Taguchi R, et al. Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue［J］. J Dermatol, 2020,47（3）:290⁃294. doi: 10. 1111/1346⁃8138.15193.
［46］	AbuHilal M, Walsh S, Shear N. Use of apremilast in combination with other therapies for treatment of chronic plaque psoriasis: a retrospective study［J］. J Cutan Med Surg, 2016,20（4）:313⁃316. doi: 10.1177/1203475416631328.
［47］	Kircik LH, Schlesinger TE, Tanghetti E. Efficacy and safety of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam with apremilast for moderate plaque psoriasis［J］. J Drugs Dermatol, 2020,19（9）:874⁃880. doi: 10.36849/JDD.2020. 10. 36849/JDD.2020.5020.
［48］	Reddy SP, Shah VV, Wu JJ. Apremilast for a psoriasis patient with HIV and hepatitis C［J］. J Eur Acad Dermatol Venereol, 2017,31（11）:e481⁃e482. doi: 10.1111/jdv.14301.
［49］	Jeon C, Nakamura M, Sekhon S, et al. Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities［J］. JAAD Case Rep, 2017,3（6）:495⁃497. doi: 10.1016/j.jdcr.2017.07.007.
［50］	Manfreda V, Esposito M, Campione E, et al. Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections［J］. Postgrad Med, 2019,131（3）:239⁃240. doi: 10.1080/00325481.2019.1575613.
［51］	Torres T, Puig L. Apremilast: a novel oral treatment for psoriasis and psoriatic arthritis［J］. Am J Clin Dermatol, 2018,19（1）:23⁃32. doi: 10.1007/s40257⁃017⁃0302⁃0.
［52］	Ghamrawi RI, Ghiam N, Wu JJ. Comparison of psoriasis guidelines for use of apremilast in the United States and Europe: a critical appraisal and comprehensive review［J］. J Dermatolog Treat, 2022,33（1）:94⁃99. doi: 10.1080/09546634.2020.1770176.
［53］	Balato N, Patruno C, Napolitano M, et al. Managing moderate⁃to⁃severe psoriasis in the elderly［J］. Drugs Aging, 2014,31（4）:233⁃238. doi: 10.1007/s40266⁃014⁃0156⁃6.
［54］	Kamel JG, Yamauchi PS. Managing mild⁃to⁃moderate psoriasis in elderly patients: role of topical treatments［J］. Drugs Aging, 2017,34（8）:583⁃588. doi: 10.1007/s40266⁃017⁃0480⁃8.
［55］	van Winden M, Ter Haar E, Groenewoud J, et al. Quality of life, treatment goals, preferences and satisfaction in older adults with psoriasis: a patient survey comparing age groups［J］. Br J Dermatol, 2021,184（4）:759⁃762. doi: 10.1111/bjd.19665.
［56］	Phan C, Beneton N, Delaunay J, et al. Real⁃world effectiveness and safety of apremilast in older patients with psoriasis［J］. Drugs Aging, 2020,37（9）:657⁃663. doi: 10.1007/s40266⁃020⁃00781⁃y.
［57］	Megna M, Fabbrocini G, Camela E, et al. Apremilast efficacy and safety in elderly psoriasis patients over a 48⁃week period［J］. J Eur Acad Dermatol Venereol, 2020,34（11）:e705⁃e707. doi: 10. 1111/jdv.16443.
［58］	Dressler C, Rosumeck S, Werner RN, et al. Methods report: European S3⁃Guideline on the systemic treatment of psoriasis vulgaris ⁃ update apremilast and secukinumab ⁃ EDF in cooperation with EADV and IPC［J］. J Eur Acad Dermatol Venereol, 2017,31（12）:1964⁃1977. doi: 10.1111/jdv.14470.
［59］	Paller AS, Hong Y, Becker EM, et al. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: results from a phase 2 open⁃label study［J］. J Am Acad Dermatol, 2020,82（2）:389⁃397. doi: 10.1016/j.jaad. 2019.08.019.
［60］	Fiorillo L，Becker E, de Lucas R, et al. Efficacy and safety results of apremilast in pediatric patients with moderate to severe plaque psoriasis: 16⁃week results from SPROUT, a phase 3, randomized, controlled study［J］. SKIN, 2023,7（2）: s109. doi: 10.25251/skin.7.supp.109.
［61］	Bernardini N, Skroza N, Marchesiello A, et al. Psoriatic patients with a history of cancer: a real⁃life experience with apremilast treatment for 104 weeks［J］. Dermatol Ther, 2022,35（10）:e15306. doi: 10.1111/dth.15306.
［62］	Fattore D, Annunziata MC, Panariello L, et al. Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast［J］. Eur J Cancer, 2019,110:107⁃109. doi: 10. 1016/j.ejca.2019.01.010.
［63］	Siciliano MA, Dastoli S, d′Apolito M, et al. Pembrolizumab⁃induced psoriasis in metastatic melanoma: activity and safety of apremilast, a case report［J］. Front Oncol, 2020,10:579445. doi: 10.3389/fonc.2020.579445.
［64］	Takama H, Shibata T, Ando Y, et al. Pembrolizumab⁃induced psoriasis vulgaris successfully treated with apremilast［J］. Eur J Dermatol, 2020,30（2）:188⁃190. doi: 10.1684/ejd.2020.3723.
［65］	Mayor Ibarguren A, Enrique EA, Diana PL, et al. Apremilast for immune checkpoint inhibitor⁃induced psoriasis: a case series［J］. JAAD Case Rep, 2021,11:84⁃89. doi: 10.1016/j.jdcr.2021. 03.015.
［66］	Mullangi S, Ponnam S, Lekkala MR, et al. A case of de novo psoriasis secondary to nivolumab in a patient with metastatic renal cell carcinoma［J］. Cureus, 2021,13（6）:e15703. doi: 10.7759/cureus.15703.
［67］	Evangelatos G, Koulouri V, Iliopoulos A, et al. Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors［J］. Ther Adv Musculoskelet Dis, 2020,12:1759720X20930116. doi: 10.1177/1759720X20930116.
［68］	Kurd SK, Troxel AB, Crits⁃Christoph P, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population⁃based cohort study［J］. Arch Dermatol, 2010,146（8）:891⁃895. doi: 10.1001/archdermatol.2010.186.
［69］	Vasilakis⁃Scaramozza C, Persson R, Hagberg KW, et al. The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database［J］. J Eur Acad Dermatol Venereol, 2020,34（8）:1755⁃1763. doi: 10.1111/jdv.16231.
［70］	Mease PJ, Hatemi G, Paris M, et al. Apremilast long⁃term safety up to 5 years from 15 pooled randomized, placebo⁃controlled studies of psoriasis, psoriatic arthritis, and Behçet′s syndrome［J］. Am J Clin Dermatol, 2023,24（5）:809⁃820. doi: 10.1007/s40257⁃023⁃00783⁃7.

[1]	Meng Xiao, Wang Junhui, Yan Zhifang, Wang Ning, Cui Bingnan. Evaluation of efficacy of a Chinese herbal mask in the treatment of melanized-type melasma by stereological measurements [J]. Chinese Journal of Dermatology, 2025, 58(1): 53-59.
[2]	Jin Lan, Qiu Yun, Wang Weijia, Kang Xiaojing, Ding Yuan. Clinical efficacy and safety of biological agents in the treatment of moderate-to-severe psoriasis in 124 elderly patients: a retrospective analysis [J]. Chinese Journal of Dermatology, 2025, 58(1): 47-52.
[3]	Wang Bo, Zheng Jie. Considerations in the treatment of elderly patients with psoriasis and atopic dermatitis using biologics and small-molecule drugs [J]. Chinese Journal of Dermatology, 2025, 58(1): 72-75.
[4]	Chen Jiaqi, Zhang Jin, Tang Jun. Relationships between coronavirus disease 2019 and psoriasis [J]. Chinese Journal of Dermatology, 2025, 58(1): 84-88.
[5]	Zou Xianbiao, Chen Jinchun, Zeng Yue, Hao Yi. Application of ultrasonography in dermatology: progress and prospects [J]. Chinese Journal of Dermatology, 2024, 57(9): 785-790.
[6]	Qiao Jiaxi, Xia Ping, Chen Liuqing. Analysis of dermoscopic and reflectance confocal microscopic features of psoriatic lesions before and after treatment with secukinumab [J]. Chinese Journal of Dermatology, 2024, 57(9): 825-829.
[7]	Lin Ziyuan, Pang Tianyi, Wu Jingwen, Jin Hui, . Role of polycyclic aromatic hydrocarbons in the occurrence and development of inflammatory skin diseases [J]. Chinese Journal of Dermatology, 2024, 57(8): 765-769.
[8]	Xie yuanyuan, Liu Yuzhen, Zeng Rong, . Application of skin imaging techniques in acne vulgaris [J]. Chinese Journal of Dermatology, 2024, 57(8): 757-760.
[9]	Dou Jinfa, Wang Jianbo, Zhang Shuai, Li Jianguo, Liu Hongwei, Zhang Shoumin. Analysis of changes in disease status and their influencing factors in patients with moderate to severe plaque psoriasis receiving biologic therapy during the coronavirus disease 2019 pandemic: a single-center cross-sectional study [J]. Chinese Journal of Dermatology, 2024, 57(8): 739-742.
[10]	Zhang Sheng, Wang Xiuwei, Chen Jianyou, Deng Wei, Zhang Haihua, Zhang Gaolei, Liu Xiaoyan, Su Wei. Efficacy of hematoporphyrin monomethyl ether-mediated photodynamic therapy in the treatment of facial port-wine stains in 15 children with Sturge-Weber syndrome [J]. Chinese Journal of Dermatology, 2024, 57(7): 616-622.
[11]	Sui Changlin, Chang Xiao, Zhao Qi, Zhu Wei. Psoriasis induced by anti-tumor targeted therapy and immunotherapy [J]. Chinese Journal of Dermatology, 2024, 57(6): 570-574.
[12]	Hu Mengyao, Li Min, Chen Sihan, Wei Xuecui, Chen Yujie, Xu Song, Chen Xu, . Different regulatory effects of S100A8/A9 expressed by keratinocytes in three common inflammatory skin injury modes [J]. Chinese Journal of Dermatology, 2024, 57(5): 435-444.
[13]	China Dermatologist Association, Combination of Traditional and Western Medicine Dermatology. Diagnosis and treatment of erythrodermic psoriasis: a Chinese expert consensus statement （2024） [J]. Chinese Journal of Dermatology, 2024, 57(5): 409-417.
[14]	Lu Jiawei, Lu Yan. Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents [J]. Chinese Journal of Dermatology, 2024, 57(5): 479-482.
[15]	Zhang Yuanwen, Sun Congqian, Pan Wendong. Off-label clinical application of botulinum toxin in dermatology [J]. Chinese Journal of Dermatology, 2024, 57(5): 471-475.

Apremilast in the treatment of plaque psoriasis

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［70］

Related Articles 15

Metrics

Comments

Recommended 10